Efficacy of Rituximab in a Patient With Partial Clinical Remission and Persistent Circulating PLA2R-Ab

Georges, Elodie; Johanet, Catherine; Plaisier, Emmanuelle; Dębiec, Hanna; Ronco, Pierre; Dahan, Karine

doi:10.1016/j.ekir.2019.03.002

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Persistence of mild hypoalbuminaemia despite non-nephrotic proteinuria is not uncommon and may indicate an active immunologic state. Beneficial effects of RTX have been described in patients with PR and persistent anti-PLA2R [ 86 ], although larger studies are needed.…”

Section: Tip 9 After Attaining Remission Monitor Risk Factors For Rel...mentioning

confidence: 99%

Ten tips on immunosuppression in primary membranous nephropathy

Trujillo,

Caravaca-Fontán,

Praga

2024

Clinical Kidney Journal

View full text Add to dashboard Cite

Membranous nephropathy (MN) management poses challenges, particularly in selecting appropriate immunosuppressive treatments (IST) and monitoring disease progression and complications. This manuscript highlights ten key tips for the management of primary MN based on current evidence and clinical experience. First, we advise against prescribing immunosuppressive treatment (IST) to patients without nephrotic syndrome, emphasizing the need for close monitoring of disease progression. Second, we recommend initiating IST in patients with persistent nephrotic syndrome or declining kidney function. Third, we suggest prescribing rituximab or rituximab combined with calcineurin inhibitors (CNI) in medium-risk patients. Fourth, we propose cyclophosphamide-based immunosuppression for high-risk patients. Fifth, we discourage the use of glucocorticoid monotherapy or mycophenolate mofetil as initial treatments. Sixth, we underscore the importance of preventing infectious complications in patients receiving IST. Seventh, we emphasize the need for personalized monitoring of IST by closely measuring kidney function, proteinuria, serum albumin, and anti-PLA2R levels. Eighth, we recommend a stepwise approach in the treatment of resistant disease. Ninth, we advise adjusting treatment for relapses based on individual risk profiles. Finally, we caution about the potential recurrence of MN after kidney transplantation and suggests appropriate monitoring and treatment strategies for post-transplantation MN. These tips provide comprehensive guidance for clinicians managing MN, aiming to optimize patient outcomes and minimize complications.

show abstract

Section: Tip 9 After Attaining Remission Monitor Risk Factors For Rel...mentioning

confidence: 99%